首页 > 最新文献

Lancet Healthy Longevity最新文献

英文 中文
Metabolic and bariatric surgery in septuagenarians 70岁老人的代谢和减肥手术。
IF 14.6 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2025-10-01 DOI: 10.1016/j.lanhl.2025.100776
Natalia Dowgiałło-Gornowicz
{"title":"Metabolic and bariatric surgery in septuagenarians","authors":"Natalia Dowgiałło-Gornowicz","doi":"10.1016/j.lanhl.2025.100776","DOIUrl":"10.1016/j.lanhl.2025.100776","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 10","pages":"Article 100776"},"PeriodicalIF":14.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145422959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Testing complex interventions for polypharmacy in real-world conditions 在现实世界条件下测试多种药物的复杂干预措施。
IF 14.6 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2025-10-01 DOI: 10.1016/j.lanhl.2025.100791
Anna Hung , Yoon Hie Kim , Juliessa M Pavon
{"title":"Testing complex interventions for polypharmacy in real-world conditions","authors":"Anna Hung , Yoon Hie Kim , Juliessa M Pavon","doi":"10.1016/j.lanhl.2025.100791","DOIUrl":"10.1016/j.lanhl.2025.100791","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 10","pages":"Article 100791"},"PeriodicalIF":14.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145446062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Care beyond caregivers: a wider spectrum of social support for older adults 护理人员以外的护理:为老年人提供更广泛的社会支持。
IF 14.6 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2025-10-01 DOI: 10.1016/j.lanhl.2025.100782
Shahmir H Ali
{"title":"Care beyond caregivers: a wider spectrum of social support for older adults","authors":"Shahmir H Ali","doi":"10.1016/j.lanhl.2025.100782","DOIUrl":"10.1016/j.lanhl.2025.100782","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 10","pages":"Article 100782"},"PeriodicalIF":14.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145348939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic and bariatric surgery in adults aged 69 years and older in England: a matched survival retrospective cohort study 英国69岁及以上成人的代谢和减肥手术:一项匹配生存回顾性队列研究。
IF 14.6 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2025-10-01 DOI: 10.1016/j.lanhl.2025.100772
Patricia M Ortega PhD , Elena Brachimi MBBS , Ahmed R Ahmed PhD , Prof Sanjay Purkayastha MD , Christos Tsironis MD , Krishna Moorthy MD , Sherif Hakky PhD , Jonathan Cousins MBBS , Harvinder Chahal PhD , Saira Hameed PhD , Prof Tricia Tan PhD , Samantha Scholtz PhD , Karen O'Donnell BSc , Louisa Brolly BSc , Ciara Price BSc , Anna Sackey MSc , Candace Bovill-Taylor BSc , Joanne Boyle BSc , Rhian Houghton BSc , Jonathan Sullivan MSc , Chioma Izzi-Engbeaya PhD

Background

The prevalence of obesity is rising alongside population ageing, yet the long-term benefits of metabolic and bariatric surgery (MBS) in older adults is unclear. We aimed to evaluate the impact of MBS on survival in individuals aged 69 years and older with obesity.

Methods

We conducted a retrospective cohort study of patients aged 69 years and older managed in a UK tertiary bariatric centre between Jan 1, 2015, and Dec 31, 2024. Patients were eligible for inclusion if they had complete clinical data. Patients who underwent MBS were compared with matched controls who did not undergo MBS. Mahalanobis distance matching was performed (1:1) using age, BMI, American Society of Anesthesiologists grade, type 2 diabetes, and cardiovascular disease. Data were retrieved from electronic health records. The primary outcome was all-cause mortality after matching. Cox regression was used to assess survival.

Findings

Of the 186 patients, 44 (24%) underwent MBS. The median age was 71 years (IQR 70–74), 114 (61%) of 186 patients were women, 72 (39%) were men, median BMI was 41 kg/m2 (IQR 37–45), and median follow-up was 39 months (IQR 22–70). After matching, 44 MBS patients were compared with 34 control participants. Matched Kaplan–Meier analysis showed superior survival among MBS patients compared with control patients (log-rank p=0·010). MBS was associated with a 68% reduction in all-cause mortality on univariate analysis (hazard ratio 0·32 [95% CI 0·11–0·92]; p=0·036) and a 75% reduction in all-cause mortality on multivariate analysis (0·25 [0·08–0·77]; p=0·015). In MBS patients, the postoperative 30-day morbidity rate was 9%: Dindo-Clavien grade III-IV complications occurred in three (7%) of 44 patients, and one person (2%) died.

Interpretation

In a specialist setting, MBS was independently associated with improved survival in individuals aged 69 years and older, with acceptable perioperative risk. Chronological age alone should not preclude consideration for MBS. These findings support further evaluation of surgical options in well selected older adults with obesity.

Funding

National Institute for Health and Care Research.
背景:随着人口老龄化,肥胖的患病率正在上升,但代谢和减肥手术(MBS)对老年人的长期益处尚不清楚。我们的目的是评估MBS对69岁及以上肥胖患者生存的影响。方法:我们对2015年1月1日至2024年12月31日期间在英国三级减肥中心管理的69岁及以上患者进行了回顾性队列研究。如果患者有完整的临床资料,则有资格纳入。接受MBS的患者与未接受MBS的匹配对照进行比较。根据年龄、BMI、美国麻醉医师学会分级、2型糖尿病和心血管疾病进行马氏距离匹配(1:1)。数据从电子健康记录中检索。配对后的主要终点是全因死亡率。采用Cox回归评估生存率。结果:186例患者中,44例(24%)接受了MBS。186例患者中,女性114例(61%),男性72例(39%),中位BMI为41 kg/m2 (IQR 37-45),中位随访时间为39个月(IQR 22-70)。匹配后,44名MBS患者与34名对照参与者进行比较。匹配Kaplan-Meier分析显示,与对照组相比,MBS患者的生存率更高(log-rank p= 0.010)。单因素分析显示,MBS与全因死亡率降低68%相关(风险比0.32 [95% CI 0.11 - 0.92], p= 0.036),多因素分析显示,全因死亡率降低75%相关(风险比0.25 [0.08 - 0.77],p= 0.015)。在MBS患者中,术后30天的发病率为9%:44例患者中有3例(7%)发生Dindo-Clavien III-IV级并发症,1例(2%)死亡。解释:在一个专业环境中,MBS与69岁及以上患者的生存率提高独立相关,围手术期风险可接受。单凭实际年龄不应排除对MBS的考虑。这些发现支持对精心挑选的老年肥胖患者进行手术选择的进一步评估。资助:国家卫生和保健研究所。
{"title":"Metabolic and bariatric surgery in adults aged 69 years and older in England: a matched survival retrospective cohort study","authors":"Patricia M Ortega PhD ,&nbsp;Elena Brachimi MBBS ,&nbsp;Ahmed R Ahmed PhD ,&nbsp;Prof Sanjay Purkayastha MD ,&nbsp;Christos Tsironis MD ,&nbsp;Krishna Moorthy MD ,&nbsp;Sherif Hakky PhD ,&nbsp;Jonathan Cousins MBBS ,&nbsp;Harvinder Chahal PhD ,&nbsp;Saira Hameed PhD ,&nbsp;Prof Tricia Tan PhD ,&nbsp;Samantha Scholtz PhD ,&nbsp;Karen O'Donnell BSc ,&nbsp;Louisa Brolly BSc ,&nbsp;Ciara Price BSc ,&nbsp;Anna Sackey MSc ,&nbsp;Candace Bovill-Taylor BSc ,&nbsp;Joanne Boyle BSc ,&nbsp;Rhian Houghton BSc ,&nbsp;Jonathan Sullivan MSc ,&nbsp;Chioma Izzi-Engbeaya PhD","doi":"10.1016/j.lanhl.2025.100772","DOIUrl":"10.1016/j.lanhl.2025.100772","url":null,"abstract":"<div><h3>Background</h3><div>The prevalence of obesity is rising alongside population ageing, yet the long-term benefits of metabolic and bariatric surgery (MBS) in older adults is unclear. We aimed to evaluate the impact of MBS on survival in individuals aged 69 years and older with obesity.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study of patients aged 69 years and older managed in a UK tertiary bariatric centre between Jan 1, 2015, and Dec 31, 2024. Patients were eligible for inclusion if they had complete clinical data. Patients who underwent MBS were compared with matched controls who did not undergo MBS. Mahalanobis distance matching was performed (1:1) using age, BMI, American Society of Anesthesiologists grade, type 2 diabetes, and cardiovascular disease. Data were retrieved from electronic health records. The primary outcome was all-cause mortality after matching. Cox regression was used to assess survival.</div></div><div><h3>Findings</h3><div>Of the 186 patients, 44 (24%) underwent MBS. The median age was 71 years (IQR 70–74), 114 (61%) of 186 patients were women, 72 (39%) were men, median BMI was 41 kg/m<sup>2</sup> (IQR 37–45), and median follow-up was 39 months (IQR 22–70). After matching, 44 MBS patients were compared with 34 control participants. Matched Kaplan–Meier analysis showed superior survival among MBS patients compared with control patients (log-rank p=0·010). MBS was associated with a 68% reduction in all-cause mortality on univariate analysis (hazard ratio 0·32 [95% CI 0·11–0·92]; p=0·036) and a 75% reduction in all-cause mortality on multivariate analysis (0·25 [0·08–0·77]; p=0·015). In MBS patients, the postoperative 30-day morbidity rate was 9%: Dindo-Clavien grade III-IV complications occurred in three (7%) of 44 patients, and one person (2%) died.</div></div><div><h3>Interpretation</h3><div>In a specialist setting, MBS was independently associated with improved survival in individuals aged 69 years and older, with acceptable perioperative risk. Chronological age alone should not preclude consideration for MBS. These findings support further evaluation of surgical options in well selected older adults with obesity.</div></div><div><h3>Funding</h3><div>National Institute for Health and Care Research.</div></div>","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 10","pages":"Article 100772"},"PeriodicalIF":14.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145422947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ageing in Africa 非洲的老龄化问题。
IF 14.6 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2025-09-01 DOI: 10.1016/j.lanhl.2025.100779
The Lancet Healthy Longevity
{"title":"Ageing in Africa","authors":"The Lancet Healthy Longevity","doi":"10.1016/j.lanhl.2025.100779","DOIUrl":"10.1016/j.lanhl.2025.100779","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 9","pages":"Article 100779"},"PeriodicalIF":14.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145309348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Age-specific population attributable fractions for frailty, functional disability, and hospitalisation in Chinese older people: an ICOPE-based prospective cohort study 中国老年人虚弱、功能残疾和住院的年龄特异性人群归因分数:一项基于icop的前瞻性队列研究
IF 14.6 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2025-09-01 DOI: 10.1016/j.lanhl.2025.100757
Ruby Yu PhD , Derek Lai MSc , Grace Leung MSc , Lok-yan Tam BNurs , Clara Cheng MASSM , Sara Kong BSc , Cecilia Tong MSc , Matthew Yu BSc , Prof Jean Woo MD
<div><h3>Background</h3><div>Declines in intrinsic capacity have been associated with increased risks of frailty, disability, and hospitalisation. We estimated population attributable fractions (PAFs) for these outcomes with respect to intrinsic capacity-related conditions and traditional modifiable risk factors in different age groups.</div></div><div><h3>Methods</h3><div>We analysed data from a territory-wide, multicentre, community-based, prospective cohort study (2023–24) in Hong Kong. Among 22 237 Chinese adults aged 60 years and older with follow-up data, we calculated age-specific PAFs for incident frailty, instrumental activities of daily living (IADL) disability, and hospitalisation associated with 13 modifiable risk factors. These risk factors included intrinsic capacity conditions, cardiometabolic conditions, and socioeconomic and lifestyle factors, and combinations of these.</div></div><div><h3>Findings</h3><div>Between March 21, 2023, and Dec 31, 2024, 47 776 participants were recruited to the study. 41 226 (86·3%) had complete baseline data for all intrinsic capacity conditions, cardiometabolic conditions, socioeconomic and lifestyle factors, demographic covariates, and outcome variables and were therefore included in our study sample. 22 237 (53·9%) of 41 226 participants completed follow-up assessments at least 6 months after baseline with a mean follow-up of 360·4 days (SD 71·6, median 348·0, IQR 307·0–399·0), 1398 (7·1%) of 19 777 participants had incident frailty, 1152 (6·0%) of 19 171 participants had incident IADL disability, and 2068 (11·1%) of 18 622 participants were hospitalised. Limited mobility was the leading risk factor associated across all outcomes (PAFs 9·8–25·3%). Depressive symptoms were a strong risk factor associated with frailty (PAF 19·1%). Age-stratified analyses revealed that limited mobility had the highest PAFs in adults aged 80 years and older, whereas depressive symptoms showed peak PAFs in those aged 60–69 years in most cases. Hypertension contributed to all outcomes (PAFs 8·4–19·6%) only in adults younger than 80 years. In adults aged 60–69 years physical activity was the predominant risk factor associated with frailty (PAF 21·9%) and disability (PAF 22·3%). The attributable risk of lower education with frailty increased with age, reaching its peak in adults aged 80 years and older (PAF 20·2%). Regarding the joint effects of the risk factors, intrinsic capacity decline was the factor associated with the highest overall attributable risk for all outcomes, exceeding the impact of cardiometabolic diseases and socioeconomic and lifestyle risk.</div></div><div><h3>Interpretation</h3><div>Our findings provide insights into age-specific risk factors for frailty, disability, and hospitalisation in older people, underlining the importance of targeted prevention strategies across age groups. Our findings further support a shift towards prioritising intrinsic capacity to better support healthy ageing at the popu
背景:内在能力的下降与虚弱、残疾和住院的风险增加有关。我们估计了不同年龄组中与内在能力相关的条件和传统可改变的危险因素有关的这些结果的人口归因分数(PAFs)。方法:我们分析了来自香港一项区域性、多中心、社区、前瞻性队列研究(2023-24)的数据。在22237名有随访数据的60岁及以上的中国成年人中,我们计算了与13个可改变的危险因素相关的事件性虚弱、日常生活工具活动(IADL)残疾和住院治疗的年龄特异性paf。这些风险因素包括内在能力状况、心脏代谢状况、社会经济和生活方式因素,以及这些因素的组合。研究结果:在2023年3月21日至2024年12月31日期间,47776名参与者被招募到这项研究中。41 226例(86.3%)患者具有所有内在能力状况、心脏代谢状况、社会经济和生活方式因素、人口统计学协变量和结局变量的完整基线数据,因此被纳入我们的研究样本。41 226名参与者中有22 237名(53.9%)在基线后至少6个月完成了随访评估,平均随访3604天(标准差76.1,中位数348.0,IQR 307·0-399·0),19 777名参与者中有1398名(7.1%)发生偶发性虚弱,19 171名参与者中有1152名(6.0%)发生偶发性IADL残疾,18 622名参与者中有2068名(11.1%)住院。活动受限是与所有结果相关的主要危险因素(paf为9.8 - 25.3%)。抑郁症状是与虚弱相关的强烈危险因素(PAF 19.1%)。年龄分层分析显示,80岁及以上的成年人行动受限的paf最高,而大多数情况下,抑郁症状的paf峰值出现在60-69岁的人群。高血压仅在80岁以下的成年人中导致所有结果(paf为8.4 - 19.6%)。在60-69岁的成年人中,体力活动是与虚弱(PAF 21.9%)和残疾(PAF 22.3%)相关的主要危险因素。低学历与虚弱的归因风险随着年龄的增长而增加,在80岁及以上的成年人中达到顶峰(PAF为20.2%)。关于风险因素的共同影响,内在能力下降是与所有结果的最高总归因风险相关的因素,超过了心脏代谢疾病以及社会经济和生活方式风险的影响。解释:我们的研究结果提供了对老年人虚弱、残疾和住院的年龄特异性风险因素的见解,强调了跨年龄组有针对性预防策略的重要性。我们的研究结果进一步支持向优先考虑内在能力的转变,以更好地支持人口层面的健康老龄化。资助:香港赛马会慈善信托基金。
{"title":"Age-specific population attributable fractions for frailty, functional disability, and hospitalisation in Chinese older people: an ICOPE-based prospective cohort study","authors":"Ruby Yu PhD ,&nbsp;Derek Lai MSc ,&nbsp;Grace Leung MSc ,&nbsp;Lok-yan Tam BNurs ,&nbsp;Clara Cheng MASSM ,&nbsp;Sara Kong BSc ,&nbsp;Cecilia Tong MSc ,&nbsp;Matthew Yu BSc ,&nbsp;Prof Jean Woo MD","doi":"10.1016/j.lanhl.2025.100757","DOIUrl":"10.1016/j.lanhl.2025.100757","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Declines in intrinsic capacity have been associated with increased risks of frailty, disability, and hospitalisation. We estimated population attributable fractions (PAFs) for these outcomes with respect to intrinsic capacity-related conditions and traditional modifiable risk factors in different age groups.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;We analysed data from a territory-wide, multicentre, community-based, prospective cohort study (2023–24) in Hong Kong. Among 22 237 Chinese adults aged 60 years and older with follow-up data, we calculated age-specific PAFs for incident frailty, instrumental activities of daily living (IADL) disability, and hospitalisation associated with 13 modifiable risk factors. These risk factors included intrinsic capacity conditions, cardiometabolic conditions, and socioeconomic and lifestyle factors, and combinations of these.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;Between March 21, 2023, and Dec 31, 2024, 47 776 participants were recruited to the study. 41 226 (86·3%) had complete baseline data for all intrinsic capacity conditions, cardiometabolic conditions, socioeconomic and lifestyle factors, demographic covariates, and outcome variables and were therefore included in our study sample. 22 237 (53·9%) of 41 226 participants completed follow-up assessments at least 6 months after baseline with a mean follow-up of 360·4 days (SD 71·6, median 348·0, IQR 307·0–399·0), 1398 (7·1%) of 19 777 participants had incident frailty, 1152 (6·0%) of 19 171 participants had incident IADL disability, and 2068 (11·1%) of 18 622 participants were hospitalised. Limited mobility was the leading risk factor associated across all outcomes (PAFs 9·8–25·3%). Depressive symptoms were a strong risk factor associated with frailty (PAF 19·1%). Age-stratified analyses revealed that limited mobility had the highest PAFs in adults aged 80 years and older, whereas depressive symptoms showed peak PAFs in those aged 60–69 years in most cases. Hypertension contributed to all outcomes (PAFs 8·4–19·6%) only in adults younger than 80 years. In adults aged 60–69 years physical activity was the predominant risk factor associated with frailty (PAF 21·9%) and disability (PAF 22·3%). The attributable risk of lower education with frailty increased with age, reaching its peak in adults aged 80 years and older (PAF 20·2%). Regarding the joint effects of the risk factors, intrinsic capacity decline was the factor associated with the highest overall attributable risk for all outcomes, exceeding the impact of cardiometabolic diseases and socioeconomic and lifestyle risk.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Interpretation&lt;/h3&gt;&lt;div&gt;Our findings provide insights into age-specific risk factors for frailty, disability, and hospitalisation in older people, underlining the importance of targeted prevention strategies across age groups. Our findings further support a shift towards prioritising intrinsic capacity to better support healthy ageing at the popu","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 9","pages":"Article 100757"},"PeriodicalIF":14.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aspirin and healthy lifespan in older people: main outcome of the ASPREE-XT observational study 阿司匹林与老年人健康寿命:ASPREE-XT观察性研究的主要结果
IF 14.6 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2025-09-01 DOI: 10.1016/j.lanhl.2025.100764
Raj C Shah MD , Prof Joanne Ryan PhD , Katherine L Webb MA , Prof Rory Wolfe PhD , Prof Andrew Chan MD , Trevor T-J Chong MBBS , Prof Michael E Ernst PharmD , Prof Sara E Espinoza MD , Olivia Flynn BMed , Song Yuin Lee MBBS , John McNeil MBBS , Prof Mark R Nelson MBBS , Suzanne G Orchard PhD , Prof Christopher M Reid PhD , Kerry Sheets MD , Prof Nigel P Stocks MBBS , Prof Nilakshi S Weerasinghe MBBS , Michelle E Wilson PhD , Robyn L Woods PhD , Prof Anne M Murray MD

Background

In the Aspirin in Reducing Events in the Elderly (ASPREE) clinical trial, low-dose aspirin was not associated with survival free of dementia and persistent physical disability (a measure of a healthy lifespan); however, there was a small increased risk of death. Given the long pre-clinical phase of many ageing conditions, we aimed to examine the legacy effect (post-trial) and the longer-term effect of aspirin versus placebo through extended follow-up in the ASPREE-XT observational study.

Methods

Between March 10, 2010, and Dec 24, 2014, 19 114 community-dwelling people in Australia and the USA, aged predominantly 70 years and older, were randomly assigned to low-dose aspirin or placebo for a median of 4·7 years as part of the ASPREE trial. Post-trial observational follow-up continued for a median of 4·3 years (IQR 4·1–4·6). All components of the primary endpoint (ie, incident dementia, persistent physical disability, and death) were adjudicated by masked expert panels. Analyses used Cox proportional hazards models with intention-to-treat.

Findings

15 633 participants (8836 [56·5%] were women, 6797 [43·5%] were men; 981 [6·3%] were not White) were eligible for and agreed to observational follow-up. There was no effect of randomisation to aspirin (34·37 events per 1000 person-years) versus placebo (33·68 per 1000 person-years) on the primary endpoint (hazard ratio [HR] 1·02; 95% CI 0·94–1·11; p=0·63) in the ASPREE-XT period. Similarly, over the period of both ASPREE and ASPREE-XT, no long-term effect of aspirin versus placebo was observed on the composite outcome of death, dementia, or persistent physical disability over almost a decade of follow-up (HR 1·01; 95% CI 0·95–1·08; p=0·65), including no long-term effect on deaths (1·06; 0·99–1·14; p=0·10). No effect of aspirin on incident major haemorrhagic events as compared with placebo was found in ASPREE-XT; however, aspirin was associated with an increased hazard for incident major haemorrhagic events across both ASPREE and ASPREE-XT (1·24; 1·10–1·39).

Interpretation

Low-dose aspirin does not appear to be effective in promoting a healthy lifespan in initially healthy, community-dwelling older people.

Funding

National Institute on Aging and the National Cancer Institute (USA).
背景:在阿司匹林减少老年人事件(ASPREE)临床试验中,低剂量阿司匹林与无痴呆和持续性身体残疾(健康寿命的一项衡量指标)的生存无关;然而,死亡风险有小幅增加。鉴于许多衰老疾病的临床前阶段较长,我们旨在通过延长ASPREE-XT观察性研究的随访,检查阿司匹林与安慰剂的遗留效应(试验后)和长期效应。方法:在2010年3月10日至2014年12月24日期间,澳大利亚和美国的19114名社区居民,年龄主要为70岁及以上,随机分配低剂量阿司匹林或安慰剂,中位时间为4.7年,作为ASPREE试验的一部分。试验后观察性随访的中位时间为4.3年(IQR为1.4 - 6)。主要终点的所有组成部分(即痴呆事件、持续性身体残疾和死亡)由蒙面专家小组裁决。分析使用带有意向治疗的Cox比例风险模型。结果:15633名参与者(8836名[56.5%]女性,6797名[43.5%]男性,981名[6.3%]非怀特)符合并同意观察性随访。在ASPREE-XT期间,阿司匹林(每1000人年34.37件事件)和安慰剂(每1000人年33.68件事件)的随机化对主要终点没有影响(风险比[HR] 1.02; 95% CI 0.94 - 1.11; p= 0.63)。同样,在ASPREE和ASPREE- xt期间,在近十年的随访中,没有观察到阿司匹林与安慰剂对死亡、痴呆或持续身体残疾的复合结局的长期影响(HR 1.01; 95% CI 0.95 - 1.08; p= 0.65),包括对死亡的长期影响(1.06;0.99 - 1.14;p= 0.10)。在ASPREE-XT中,与安慰剂相比,阿司匹林对大出血事件的发生率没有影响;然而,阿司匹林与ASPREE和ASPREE- xt中发生重大出血事件的风险增加相关(1.24;1.10 - 1.39)。解释:在原本健康的社区老年人中,低剂量阿司匹林似乎不能有效地促进健康的寿命。资助:美国国家老龄研究所和国家癌症研究所。
{"title":"Aspirin and healthy lifespan in older people: main outcome of the ASPREE-XT observational study","authors":"Raj C Shah MD ,&nbsp;Prof Joanne Ryan PhD ,&nbsp;Katherine L Webb MA ,&nbsp;Prof Rory Wolfe PhD ,&nbsp;Prof Andrew Chan MD ,&nbsp;Trevor T-J Chong MBBS ,&nbsp;Prof Michael E Ernst PharmD ,&nbsp;Prof Sara E Espinoza MD ,&nbsp;Olivia Flynn BMed ,&nbsp;Song Yuin Lee MBBS ,&nbsp;John McNeil MBBS ,&nbsp;Prof Mark R Nelson MBBS ,&nbsp;Suzanne G Orchard PhD ,&nbsp;Prof Christopher M Reid PhD ,&nbsp;Kerry Sheets MD ,&nbsp;Prof Nigel P Stocks MBBS ,&nbsp;Prof Nilakshi S Weerasinghe MBBS ,&nbsp;Michelle E Wilson PhD ,&nbsp;Robyn L Woods PhD ,&nbsp;Prof Anne M Murray MD","doi":"10.1016/j.lanhl.2025.100764","DOIUrl":"10.1016/j.lanhl.2025.100764","url":null,"abstract":"<div><h3>Background</h3><div>In the Aspirin in Reducing Events in the Elderly (ASPREE) clinical trial, low-dose aspirin was not associated with survival free of dementia and persistent physical disability (a measure of a healthy lifespan); however, there was a small increased risk of death. Given the long pre-clinical phase of many ageing conditions, we aimed to examine the legacy effect (post-trial) and the longer-term effect of aspirin versus placebo through extended follow-up in the ASPREE-XT observational study.</div></div><div><h3>Methods</h3><div>Between March 10, 2010, and Dec 24, 2014, 19 114 community-dwelling people in Australia and the USA, aged predominantly 70 years and older, were randomly assigned to low-dose aspirin or placebo for a median of 4·7 years as part of the ASPREE trial. Post-trial observational follow-up continued for a median of 4·3 years (IQR 4·1–4·6). All components of the primary endpoint (ie, incident dementia, persistent physical disability, and death) were adjudicated by masked expert panels. Analyses used Cox proportional hazards models with intention-to-treat.</div></div><div><h3>Findings</h3><div>15 633 participants (8836 [56·5%] were women, 6797 [43·5%] were men; 981 [6·3%] were not White) were eligible for and agreed to observational follow-up. There was no effect of randomisation to aspirin (34·37 events per 1000 person-years) versus placebo (33·68 per 1000 person-years) on the primary endpoint (hazard ratio [HR] 1·02; 95% CI 0·94–1·11; p=0·63) in the ASPREE-XT period. Similarly, over the period of both ASPREE and ASPREE-XT, no long-term effect of aspirin versus placebo was observed on the composite outcome of death, dementia, or persistent physical disability over almost a decade of follow-up (HR 1·01; 95% CI 0·95–1·08; p=0·65), including no long-term effect on deaths (1·06; 0·99–1·14; p=0·10). No effect of aspirin on incident major haemorrhagic events as compared with placebo was found in ASPREE-XT; however, aspirin was associated with an increased hazard for incident major haemorrhagic events across both ASPREE and ASPREE-XT (1·24; 1·10–1·39).</div></div><div><h3>Interpretation</h3><div>Low-dose aspirin does not appear to be effective in promoting a healthy lifespan in initially healthy, community-dwelling older people.</div></div><div><h3>Funding</h3><div>National Institute on Aging and the National Cancer Institute (USA).</div></div>","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 9","pages":"Article 100764"},"PeriodicalIF":14.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145226141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrating exercise and medication management in geriatric care: a holistic strategy to enhance health outcomes and reduce polypharmacy 在老年护理中整合运动和药物管理:提高健康结果和减少多药的整体策略。
IF 14.6 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2025-09-01 DOI: 10.1016/j.lanhl.2025.100763
Prof Mikel Izquierdo PhD , Robinsón Ramírez-Vélez PhD , Prof Maria A Fiatarone Singh MD FRACP
Integrating exercise prescriptions with medication management represents a novel approach for enhancing health and function, optimising medication effectiveness, and reducing adverse drug reactions and polypharmacy in older adults (ie, those aged ≥60 years). This Personal View highlights the need for a comprehensive assessment of lifestyle, diagnoses, geriatric syndromes, and medications with an emphasis on fully incorporating exercise treatment into geriatric care. Exercise is an alternative to less effective or unsafe medications for many conditions, including depression, anxiety, insomnia, osteoarthritis, and dementia. Exercise is an important adjunct to pharmacotherapy for many common chronic conditions such as coronary artery disease, heart failure, diabetes, osteoporosis, cancer, and chronic obstructive pulmonary disease. Adding exercise to drug management can mitigate adverse drug reactions, enhance medication compliance, and reduce the adverse effects of sedentary behaviour and ageing processes on chronic disease expression. Targeted exercise programmes have also been shown to ameliorate drug-induced side-effects, including anorexia, falls, sarcopenia, osteoporosis, and orthostatic hypotension, and to overcome constraints such as reduced aerobic fitness, balance impairment, and muscle atrophy due to some medications. Health-care professionals require additional training and support to ensure that exercise assumes a key, central role in older adults with multimorbidity and polypharmacy, as supported by the current literature. This Personal View describes practical approaches to incorporating exercise into clinical practice as a step towards an integrated geriatric care model, with the ultimate aim of increasing health span and minimising disability.
在老年人(即年龄≥60岁的老年人)中,将运动处方与药物管理相结合是一种增强健康和功能、优化药物有效性、减少药物不良反应和多药的新方法。本个人观点强调需要对生活方式、诊断、老年综合症和药物进行全面评估,并强调将运动治疗充分纳入老年护理。对于许多疾病,包括抑郁、焦虑、失眠、骨关节炎和痴呆,锻炼是一种不太有效或不安全的药物的替代品。对于许多常见的慢性疾病,如冠状动脉疾病、心力衰竭、糖尿病、骨质疏松症、癌症和慢性阻塞性肺病,运动是药物治疗的重要辅助手段。在药物管理中增加运动可以减轻药物不良反应,增强药物依从性,并减少久坐行为和衰老过程对慢性疾病表达的不利影响。有针对性的锻炼计划也被证明可以改善药物引起的副作用,包括厌食症、跌倒、肌肉减少症、骨质疏松症和体位性低血压,并克服一些药物引起的有氧适能降低、平衡障碍和肌肉萎缩等限制。卫生保健专业人员需要额外的培训和支持,以确保锻炼在患有多种疾病和多种药物的老年人中发挥关键的核心作用,正如当前文献所支持的那样。本个人观点描述了将锻炼纳入临床实践的实际方法,作为迈向综合老年护理模式的一步,其最终目标是增加健康寿命并最大限度地减少残疾。
{"title":"Integrating exercise and medication management in geriatric care: a holistic strategy to enhance health outcomes and reduce polypharmacy","authors":"Prof Mikel Izquierdo PhD ,&nbsp;Robinsón Ramírez-Vélez PhD ,&nbsp;Prof Maria A Fiatarone Singh MD FRACP","doi":"10.1016/j.lanhl.2025.100763","DOIUrl":"10.1016/j.lanhl.2025.100763","url":null,"abstract":"<div><div>Integrating exercise prescriptions with medication management represents a novel approach for enhancing health and function, optimising medication effectiveness, and reducing adverse drug reactions and polypharmacy in older adults (ie, those aged ≥60 years). This Personal View highlights the need for a comprehensive assessment of lifestyle, diagnoses, geriatric syndromes, and medications with an emphasis on fully incorporating exercise treatment into geriatric care. Exercise is an alternative to less effective or unsafe medications for many conditions, including depression, anxiety, insomnia, osteoarthritis, and dementia. Exercise is an important adjunct to pharmacotherapy for many common chronic conditions such as coronary artery disease, heart failure, diabetes, osteoporosis, cancer, and chronic obstructive pulmonary disease. Adding exercise to drug management can mitigate adverse drug reactions, enhance medication compliance, and reduce the adverse effects of sedentary behaviour and ageing processes on chronic disease expression. Targeted exercise programmes have also been shown to ameliorate drug-induced side-effects, including anorexia, falls, sarcopenia, osteoporosis, and orthostatic hypotension, and to overcome constraints such as reduced aerobic fitness, balance impairment, and muscle atrophy due to some medications. Health-care professionals require additional training and support to ensure that exercise assumes a key, central role in older adults with multimorbidity and polypharmacy, as supported by the current literature. This Personal View describes practical approaches to incorporating exercise into clinical practice as a step towards an integrated geriatric care model, with the ultimate aim of increasing health span and minimising disability.</div></div>","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 9","pages":"Article 100763"},"PeriodicalIF":14.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Lancet Healthy Longev 2023; 4: e83–90 《柳叶刀健康longgev 2023》更正;4: e83 - 90。
IF 14.6 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2025-09-01 DOI: 10.1016/j.lanhl.2025.100754
{"title":"Correction to Lancet Healthy Longev 2023; 4: e83–90","authors":"","doi":"10.1016/j.lanhl.2025.100754","DOIUrl":"10.1016/j.lanhl.2025.100754","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 9","pages":"Article 100754"},"PeriodicalIF":14.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145313868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of an Iyengar yoga-based exercise programme versus a seated yoga relaxation programme on falls in people aged 60 years and older (SAGE): a pragmatic, two-arm, parallel randomised controlled trial 以艾扬格瑜伽为基础的锻炼计划与坐姿瑜伽放松计划对60岁及以上老年人跌倒的影响(SAGE):一项实用的、双臂的、平行的随机对照试验。
IF 14.6 Q1 GERIATRICS & GERONTOLOGY Pub Date : 2025-09-01 DOI: 10.1016/j.lanhl.2025.100749
Juliana S Oliveira PhD , Prof Catherine Sherrington PhD , Prof Stephen R Lord PhD , Giane C Camara MPhil , Shannon Colley BA , Courtney A West MHC , Abby Haynes PhD , Heidi Gilchrist PhD , Wing S Kwok PhD , Louise MN Pearce PhD , Geraldine Wallbank BAppSc , Mallory Trent PhD , Prof Adrian Bauman PhD , Anne C Grunseit PhD , Prof Kaarin J Anstey PhD , Prof Anne Tiedemann PhD

Background

Exercises targeting balance and strength are proven to prevent falls. Yoga is growing in popularity and can improve balance and mobility in older adults, but its effects on falls have not been rigorously tested. In this study, we aimed to compare the effects of Iyengar yoga-based exercise and seated relaxation yoga on the rate of falls among older adults.

Methods

This pragmatic, two-arm, parallel randomised controlled trial recruited Australian community-dwelling people aged 60 years and older who were not currently practising yoga and who lived independently. Participants were randomly assigned (1:1) to the intervention (Iyengar yoga-based exercise) or control (seated relaxation yoga) group using a computer-generated sequence. Participants and yoga instructors were unmasked, but research staff verifying falls data and assessing goal attainment were masked to group allocation. Intervention participants received 80 supervised, 1-h, twice-weekly yoga classes over 12 months, and were encouraged to undertake unsupervised practice on 2 additional days per week. Control participants attended two 1-h supervised workshops focused on seated breathing and stretching. Most classes were held online due to the COVID-19 pandemic. The primary outcome was fall rate per year. Secondary outcomes were mental wellbeing, physical activity, quality of life, balance self-confidence, physical function, sleep quality, pain, and goal attainment, all assessed in the intention-to-treat population. The study protocol was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12619001183178).

Findings

Between Oct 3, 2019, and Oct 28, 2021, 2182 older adults expressed their interest in participating, 810 were assessed for eligibility, 110 were excluded, and 700 were randomly assigned to either the Iyengar yoga exercise programme or the control group (seated yoga relaxation programme; 350 participants per group). The mean age of participants was 67 years (SD 5·2), and 570 (81%) were female and 130 (19%) were male. Six intervention participants reported musculoskeletal-related adverse events associated with the yoga programme, and no serious adverse events occurred. Contrary to expectations, there was a higher fall rate in the intervention group than in the control group (0·87 vs 0·64 falls per person-year; incidence rate ratio 1·33 [95% CI 1·01–1·75; p=0·044]). The intervention improved the number of hours per week of planned physical activity (mean difference 0·96 h per week [95% CI 0·43–1·49]; p<0·0001), self-reported balance confidence (mean difference 2·94 [0·60–5·28]; p=0·014), and goal attainment (mean difference 0·60 [0·26–0·94]; p=0·0006). No significant between-group differences were identified for other secondary outcomes.

Interpretation

This Iyengar yoga-based programme should not be recommended for fall prevention in its
背景:以平衡和力量为目标的锻炼已被证明可以防止跌倒。瑜伽越来越受欢迎,可以改善老年人的平衡和活动能力,但它对摔倒的影响还没有经过严格的测试。在这项研究中,我们旨在比较艾扬格瑜伽和坐姿放松瑜伽对老年人跌倒率的影响。方法:这项实用的,双臂,平行随机对照试验招募了60岁及以上的澳大利亚社区居民,他们目前没有练习瑜伽,并且独立生活。参与者按照电脑生成的顺序被随机分配到干预组(基于艾扬格瑜伽的锻炼)和对照组(坐式放松瑜伽)。参与者和瑜伽教练没有戴面具,但验证跌倒数据和评估目标实现情况的研究人员对小组分配不戴面具。干预参与者在12个月的时间里接受了80次有监督的、每周两次的1小时瑜伽课程,并被鼓励每周额外进行2天的无监督练习。对照组参与者参加了两个1小时的有监督的讲习班,重点是坐姿呼吸和伸展。受新型冠状病毒感染症(COVID-19)疫情影响,大部分课程都在网上进行。主要观察指标为每年的下降率。次要结果是心理健康、身体活动、生活质量、平衡自信、身体功能、睡眠质量、疼痛和目标实现,所有这些都是在意向治疗人群中评估的。该研究方案已在澳大利亚新西兰临床试验登记处注册(ACTRN12619001183178)。研究结果:在2019年10月3日至2021年10月28日期间,2182名老年人表达了参与的兴趣,810人被评估为合格,110人被排除,700人被随机分配到艾杨格瑜伽锻炼项目或对照组(坐式瑜伽放松项目,每组350人)。参与者的平均年龄为67岁(SD 5.2),女性570人(81%),男性130人(19%)。6名干预参与者报告了与瑜伽计划相关的肌肉骨骼相关不良事件,没有发生严重的不良事件。与预期相反,干预组的跌倒率高于对照组(0.87 vs 0.64 /人/年;发病率比1.33 [95% CI 1.01 - 1.75; p= 0.044])。干预提高了每周计划体育活动的小时数(平均差异为0.96小时/周[95% CI 0.43 -1·49]);解释:这种基于艾扬格瑜伽的计划不应以目前的形式推荐用于预防跌倒。改进的动态平衡规划和预防跌倒战略值得调查。资助:国家卫生和医学研究委员会。
{"title":"The effect of an Iyengar yoga-based exercise programme versus a seated yoga relaxation programme on falls in people aged 60 years and older (SAGE): a pragmatic, two-arm, parallel randomised controlled trial","authors":"Juliana S Oliveira PhD ,&nbsp;Prof Catherine Sherrington PhD ,&nbsp;Prof Stephen R Lord PhD ,&nbsp;Giane C Camara MPhil ,&nbsp;Shannon Colley BA ,&nbsp;Courtney A West MHC ,&nbsp;Abby Haynes PhD ,&nbsp;Heidi Gilchrist PhD ,&nbsp;Wing S Kwok PhD ,&nbsp;Louise MN Pearce PhD ,&nbsp;Geraldine Wallbank BAppSc ,&nbsp;Mallory Trent PhD ,&nbsp;Prof Adrian Bauman PhD ,&nbsp;Anne C Grunseit PhD ,&nbsp;Prof Kaarin J Anstey PhD ,&nbsp;Prof Anne Tiedemann PhD","doi":"10.1016/j.lanhl.2025.100749","DOIUrl":"10.1016/j.lanhl.2025.100749","url":null,"abstract":"<div><h3>Background</h3><div>Exercises targeting balance and strength are proven to prevent falls. Yoga is growing in popularity and can improve balance and mobility in older adults, but its effects on falls have not been rigorously tested. In this study, we aimed to compare the effects of Iyengar yoga-based exercise and seated relaxation yoga on the rate of falls among older adults.</div></div><div><h3>Methods</h3><div>This pragmatic, two-arm, parallel randomised controlled trial recruited Australian community-dwelling people aged 60 years and older who were not currently practising yoga and who lived independently. Participants were randomly assigned (1:1) to the intervention (Iyengar yoga-based exercise) or control (seated relaxation yoga) group using a computer-generated sequence. Participants and yoga instructors were unmasked, but research staff verifying falls data and assessing goal attainment were masked to group allocation. Intervention participants received 80 supervised, 1-h, twice-weekly yoga classes over 12 months, and were encouraged to undertake unsupervised practice on 2 additional days per week. Control participants attended two 1-h supervised workshops focused on seated breathing and stretching. Most classes were held online due to the COVID-19 pandemic. The primary outcome was fall rate per year. Secondary outcomes were mental wellbeing, physical activity, quality of life, balance self-confidence, physical function, sleep quality, pain, and goal attainment, all assessed in the intention-to-treat population. The study protocol was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12619001183178).</div></div><div><h3>Findings</h3><div>Between Oct 3, 2019, and Oct 28, 2021, 2182 older adults expressed their interest in participating, 810 were assessed for eligibility, 110 were excluded, and 700 were randomly assigned to either the Iyengar yoga exercise programme or the control group (seated yoga relaxation programme; 350 participants per group). The mean age of participants was 67 years (SD 5·2), and 570 (81%) were female and 130 (19%) were male. Six intervention participants reported musculoskeletal-related adverse events associated with the yoga programme, and no serious adverse events occurred. Contrary to expectations, there was a higher fall rate in the intervention group than in the control group (0·87 <em>vs</em> 0·64 falls per person-year; incidence rate ratio 1·33 [95% CI 1·01–1·75; p=0·044]). The intervention improved the number of hours per week of planned physical activity (mean difference 0·96 h per week [95% CI 0·43–1·49]; p&lt;0·0001), self-reported balance confidence (mean difference 2·94 [0·60–5·28]; p=0·014), and goal attainment (mean difference 0·60 [0·26–0·94]; p=0·0006). No significant between-group differences were identified for other secondary outcomes.</div></div><div><h3>Interpretation</h3><div>This Iyengar yoga-based programme should not be recommended for fall prevention in its ","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 9","pages":"Article 100749"},"PeriodicalIF":14.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145179234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Lancet Healthy Longevity
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1